Stockreport

https://seekingalpha.com/article/4765289-ocular-therapeutix-axpaxlis-dual-trial-strategy-and-blockbuster-potential [Seeking Alpha]

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catal [Read more]